2024

Drew, Y. et al. (2024) Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study. Clinical Cancer Research, 30(1), pp. 50-62. (doi: 10.1158/1078-0432.ccr-23-2249) (PMID:37939124) (PMCID:PMC10767301)

2023

Alizzi, Z. et al. (2023) Description of a retrospective cohort of epithelial ovarian cancer patients with brain metastases: evaluation of the role of PARP inhibitors in this setting. Journal of Clinical Medicine, 12(7), 2497. (doi: 10.3390/jcm12072497) (PMID:37048581) (PMCID:PMC10095324)

2022

Ho, G.-Y. et al. (2022) Epithelial-to-mesenchymal transition supports ovarian carcinosarcoma tumorigenesis and confers sensitivity to microtubule-targeting with eribulin. Cancer Research, 82(23), pp. 4457-4473. (doi: 10.1158/0008-5472.can-21-4012) (PMID:36206301) (PMCID:PMC9716257)

Hollis, R. L. et al. (2022) Multiomic characterisation of high grade serous ovarian carcinoma enables high resolution patient stratification. Clinical Cancer Research, 28(16), pp. 3546-3556. (doi: 10.1158/1078-0432.CCR-22-0368) (PMID:35696721)

Spiliopoulou, P. et al. (2022) Dual G9A/EZH2 inhibition stimulates anti-tumour immune response in ovarian high grade serous carcinoma. Molecular Cancer Therapeutics, 21(4), pp. 522-534. (doi: 10.1158/1535-7163.MCT-21-0743) (PMID:35131874) (PMCID:PMC9377747)

Wohlmuth, C. et al. (2022) CA-125 levels are predictive of survival in low-grade serous ovarian cancer—a multicenter analysis. Cancers, 14(8), 1954. (doi: 10.3390/cancers14081954) (PMID:35454861) (PMCID:PMC9024456)

2021

Moreno, V. et al. (2021) Safety and efficacy of the tumor-selective adenovirus enadenotucirev with or without paclitaxel in platinum-resistant ovarian cancer: a phase 1 clinical trial. Journal for ImmunoTherapy of Cancer, 9(12), e003645. (doi: 10.1136/jitc-2021-003645) (PMID:34893524) (PMCID:PMC8666888)

Spiliopoulou, P. , Hinsley, S. , Mcneish, I. A. , Roxburgh, P. and Glasspool, R. (2021) Metronomic oral cyclophosphamide in relapsed ovarian cancer. International Journal of Gynecological Cancer, 31, pp. 1037-1044. (doi: 10.1136/ijgc-2021-002467) (PMID:34016703)

Ewing, A. et al. (2021) Structural variants at the BRCA1/2 loci are a common source of homologous repair deficiency in high grade serous ovarian carcinoma. Clinical Cancer Research, 27(11), pp. 3201-3214. (doi: 10.1158/1078-0432.CCR-20-4068) (PMID:33741650) (PMCID:PMC7610896)

2020

Litchfield, K. et al. (2020) Representative sequencing: unbiased sampling of solid tumor tissue. Cell Reports, 31(5), 107550. (doi: 10.1016/j.celrep.2020.107550) (PMID:32375028)

2017

Wilson, R. H. et al. (2017) A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours. British Journal of Cancer, 116(884), (doi: 10.1038/bjc.2017.36) (PMID:28222073)

2014

Roxburgh, P. , Lumsden, G. R., Paul, J. , Harden, S., Sweeting, L., James, A., Crellin, A., Morrison, R., Evans, T. R. J. and McDonald, A. C. (2014) A phase I and pharmacokinetic study of capecitabine in combination with radiotherapy in patients with localised inoperable pancreatic cancer. Cancer Chemotherapy and Pharmacology, 74(1), pp. 131-139. (doi: 10.1007/s00280-014-2470-4) (PMID:24819683)

Roxburgh, P. , Cowell, G. M. and Glasspool, R. M. (2014) Concerning the feasibility of obtaining biopsies for research in relapsed ovarian cancer. International Journal of Gynecological Cancer, 24(1), pp. 2-3. (doi: 10.1097/IGC.0000000000000060)

Paulus-Hock, V., Cheung, E. C., Roxburgh, P. , Vousden, K. H. and Hock, A. K. (2014) iRFP is a real time marker for transformation based assays in high content screening. PLoS ONE, 9(6), e98399. (doi: 10.1371/journal.pone.0098399) (PMID:24887316) (PMCID:PMC4041769)

Roxburgh, P. and Glasspool, R. (2014) Squamous carcinoma of the ovary. Current Oncology Reports, 16(413), (doi: 10.1007/s11912-014-0413-1)

2013

Dickens, M.P., Roxburgh, P. , Hock, A., Mezna, M., Kellam, B., Vousden, K.H. and Fischer, P.M. (2013) 5-deazaflavin derivatives as inhibitors of p53 ubiquitination by HDM2. Bioorganic and Medicinal Chemistry, 21(22), pp. 6868-6877. (doi: 10.1016/j.bmc.2013.09.038)

Lindsay, C. R., Roxburgh, P. and Graham, J. (2013) How do we optimally use cetuximab in first-line treatment for metastatic colorectal cancer? Future Oncology, 9(6), pp. 825-829. (doi: 10.2217/fon.13.60)

Tan, D.S.P., Yap, T.A., Hutka, M., Roxburgh, P. , Ang, J., Banerjee, S., Grzybowska, E., Gourley, C., Gore, M.E. and Kaye, S.B. (2013) Implications of BRCA1 and BRCA2 mutations for the efficacy of paclitaxel monotherapy in advanced ovarian cancer. European Journal of Cancer, 49(6), pp. 1246-1253. (doi: 10.1016/j.ejca.2012.11.016)

Roxburgh, P. , Hock, A.K., Dickens, M.P., Mezna, M., Fischer, P.M. and Vousden, K.H. (2013) Small molecules that bind the Mdm2 RING stabilize and activate p53. Carcinogenesis, 34(3), pp. 791-798. (doi: 10.1093/carcin/bgs092)

2011

Lolkema, M. P. et al. (2011) A phase I study of the combination of intravenous reovirus type 3 Dearing and gemcitabine in patients with advanced cancer. Clinical Cancer Research, 17(3), pp. 581-588. (doi: 10.1158/1078-0432.CCR-10-2159)

Roxburgh, P. , Reed, N. and Glasspool, R. (2011) Experience of weekly carboplatin and paclitaxel in treatment resistant ovarian cancer. European Journal of Clinical and Medical Oncology, 3(4),

2010

Gourley, C. et al. (2010) Increased incidence of visceral metastases in Scottish patients with BRCA1/2-defective ovarian cancer: an extension of the ovarian BRCAness phenotype. Journal of Clinical Oncology, 28(15), pp. 2505-2511. (doi: 10.1200/JCO.2009.25.1082)

2008

Roxburgh, P. and Evans, T. (2008) Systemic therapy of hepatocellular carcinoma: Are we making progress? Advances in Therapy, 25(11), pp. 1089-1104. (doi: 10.1007/s12325-008-0113-z)

Articles

Drew, Y. et al. (2024) Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study. Clinical Cancer Research, 30(1), pp. 50-62. (doi: 10.1158/1078-0432.ccr-23-2249) (PMID:37939124) (PMCID:PMC10767301)

Alizzi, Z. et al. (2023) Description of a retrospective cohort of epithelial ovarian cancer patients with brain metastases: evaluation of the role of PARP inhibitors in this setting. Journal of Clinical Medicine, 12(7), 2497. (doi: 10.3390/jcm12072497) (PMID:37048581) (PMCID:PMC10095324)

Ho, G.-Y. et al. (2022) Epithelial-to-mesenchymal transition supports ovarian carcinosarcoma tumorigenesis and confers sensitivity to microtubule-targeting with eribulin. Cancer Research, 82(23), pp. 4457-4473. (doi: 10.1158/0008-5472.can-21-4012) (PMID:36206301) (PMCID:PMC9716257)

Hollis, R. L. et al. (2022) Multiomic characterisation of high grade serous ovarian carcinoma enables high resolution patient stratification. Clinical Cancer Research, 28(16), pp. 3546-3556. (doi: 10.1158/1078-0432.CCR-22-0368) (PMID:35696721)

Spiliopoulou, P. et al. (2022) Dual G9A/EZH2 inhibition stimulates anti-tumour immune response in ovarian high grade serous carcinoma. Molecular Cancer Therapeutics, 21(4), pp. 522-534. (doi: 10.1158/1535-7163.MCT-21-0743) (PMID:35131874) (PMCID:PMC9377747)

Wohlmuth, C. et al. (2022) CA-125 levels are predictive of survival in low-grade serous ovarian cancer—a multicenter analysis. Cancers, 14(8), 1954. (doi: 10.3390/cancers14081954) (PMID:35454861) (PMCID:PMC9024456)

Moreno, V. et al. (2021) Safety and efficacy of the tumor-selective adenovirus enadenotucirev with or without paclitaxel in platinum-resistant ovarian cancer: a phase 1 clinical trial. Journal for ImmunoTherapy of Cancer, 9(12), e003645. (doi: 10.1136/jitc-2021-003645) (PMID:34893524) (PMCID:PMC8666888)

Spiliopoulou, P. , Hinsley, S. , Mcneish, I. A. , Roxburgh, P. and Glasspool, R. (2021) Metronomic oral cyclophosphamide in relapsed ovarian cancer. International Journal of Gynecological Cancer, 31, pp. 1037-1044. (doi: 10.1136/ijgc-2021-002467) (PMID:34016703)

Ewing, A. et al. (2021) Structural variants at the BRCA1/2 loci are a common source of homologous repair deficiency in high grade serous ovarian carcinoma. Clinical Cancer Research, 27(11), pp. 3201-3214. (doi: 10.1158/1078-0432.CCR-20-4068) (PMID:33741650) (PMCID:PMC7610896)

Litchfield, K. et al. (2020) Representative sequencing: unbiased sampling of solid tumor tissue. Cell Reports, 31(5), 107550. (doi: 10.1016/j.celrep.2020.107550) (PMID:32375028)

Wilson, R. H. et al. (2017) A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours. British Journal of Cancer, 116(884), (doi: 10.1038/bjc.2017.36) (PMID:28222073)

Roxburgh, P. , Lumsden, G. R., Paul, J. , Harden, S., Sweeting, L., James, A., Crellin, A., Morrison, R., Evans, T. R. J. and McDonald, A. C. (2014) A phase I and pharmacokinetic study of capecitabine in combination with radiotherapy in patients with localised inoperable pancreatic cancer. Cancer Chemotherapy and Pharmacology, 74(1), pp. 131-139. (doi: 10.1007/s00280-014-2470-4) (PMID:24819683)

Roxburgh, P. , Cowell, G. M. and Glasspool, R. M. (2014) Concerning the feasibility of obtaining biopsies for research in relapsed ovarian cancer. International Journal of Gynecological Cancer, 24(1), pp. 2-3. (doi: 10.1097/IGC.0000000000000060)

Paulus-Hock, V., Cheung, E. C., Roxburgh, P. , Vousden, K. H. and Hock, A. K. (2014) iRFP is a real time marker for transformation based assays in high content screening. PLoS ONE, 9(6), e98399. (doi: 10.1371/journal.pone.0098399) (PMID:24887316) (PMCID:PMC4041769)

Roxburgh, P. and Glasspool, R. (2014) Squamous carcinoma of the ovary. Current Oncology Reports, 16(413), (doi: 10.1007/s11912-014-0413-1)

Dickens, M.P., Roxburgh, P. , Hock, A., Mezna, M., Kellam, B., Vousden, K.H. and Fischer, P.M. (2013) 5-deazaflavin derivatives as inhibitors of p53 ubiquitination by HDM2. Bioorganic and Medicinal Chemistry, 21(22), pp. 6868-6877. (doi: 10.1016/j.bmc.2013.09.038)

Lindsay, C. R., Roxburgh, P. and Graham, J. (2013) How do we optimally use cetuximab in first-line treatment for metastatic colorectal cancer? Future Oncology, 9(6), pp. 825-829. (doi: 10.2217/fon.13.60)

Tan, D.S.P., Yap, T.A., Hutka, M., Roxburgh, P. , Ang, J., Banerjee, S., Grzybowska, E., Gourley, C., Gore, M.E. and Kaye, S.B. (2013) Implications of BRCA1 and BRCA2 mutations for the efficacy of paclitaxel monotherapy in advanced ovarian cancer. European Journal of Cancer, 49(6), pp. 1246-1253. (doi: 10.1016/j.ejca.2012.11.016)

Roxburgh, P. , Hock, A.K., Dickens, M.P., Mezna, M., Fischer, P.M. and Vousden, K.H. (2013) Small molecules that bind the Mdm2 RING stabilize and activate p53. Carcinogenesis, 34(3), pp. 791-798. (doi: 10.1093/carcin/bgs092)

Lolkema, M. P. et al. (2011) A phase I study of the combination of intravenous reovirus type 3 Dearing and gemcitabine in patients with advanced cancer. Clinical Cancer Research, 17(3), pp. 581-588. (doi: 10.1158/1078-0432.CCR-10-2159)

Roxburgh, P. , Reed, N. and Glasspool, R. (2011) Experience of weekly carboplatin and paclitaxel in treatment resistant ovarian cancer. European Journal of Clinical and Medical Oncology, 3(4),

Gourley, C. et al. (2010) Increased incidence of visceral metastases in Scottish patients with BRCA1/2-defective ovarian cancer: an extension of the ovarian BRCAness phenotype. Journal of Clinical Oncology, 28(15), pp. 2505-2511. (doi: 10.1200/JCO.2009.25.1082)

Roxburgh, P. and Evans, T. (2008) Systemic therapy of hepatocellular carcinoma: Are we making progress? Advances in Therapy, 25(11), pp. 1089-1104. (doi: 10.1007/s12325-008-0113-z)